Comparative Pharmacology
Head-to-head clinical analysis: ADZENYS ER versus DEXEDRINE SPANSULE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADZENYS ER versus DEXEDRINE SPANSULE.
ADZENYS ER vs DEXEDRINE SPANSULE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ADZENYS ER is a central nervous system (CNS) stimulant that blocks the reuptake of norepinephrine and dopamine into presynaptic neurons, increasing their concentrations in the synaptic cleft.
Dextroamphetamine is a central nervous system (CNS) stimulant that increases synaptic concentrations of norepinephrine and dopamine by blocking their reuptake and promoting release from presynaptic terminals.
Adults: Initial 5-10 mg orally once daily; titrate in 5-10 mg increments weekly to optimal response; max 60 mg/day.
5-60 mg orally once daily in the morning, using extended-release capsules.
None Documented
None Documented
6-8 hours in adults; in children 3-6 hours, requiring twice-daily dosing for sustained effect
Terminal elimination half-life is 6-8 hours in adults, 10-13 hours in children, and prolonged in alkaline urine (up to 16-20 hours) due to enhanced tubular reabsorption. In hepatic impairment, half-life may extend to 12-15 hours. Steady-state is reached within 2-3 days.
70% renal (30% unchanged, 40% as metabolites), 30% fecal/biliary
Renal excretion of unchanged drug (approximately 30-40% unchanged) and hepatic metabolism to inactive metabolites (primarily hippuric acid, benzoic acid, and hydroxylated derivatives). About 90% of a dose is excreted in urine within 48 hours, with 10-15% as unchanged dextroamphetamine; minor biliary/fecal elimination (<5% total).
Category C
Category C
CNS Stimulant
CNS Stimulant